B-Cell Lymphoblastic Leukemia
Oncology·MeSH: Burkitt Lymphoma
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| tecartus | GH Research PLC (GHRS) |
Frequently asked questions
How many drugs are in development for B-Cell Lymphoblastic Leukemia?
BioSniper tracks 1 drug in development for B-Cell Lymphoblastic Leukemia across 1 company.
How many clinical trials target B-Cell Lymphoblastic Leukemia?
There are 1 clinical trial targeting B-Cell Lymphoblastic Leukemia tracked by BioSniper.
What is the prevalence of B-Cell Lymphoblastic Leukemia?
The estimated prevalence of B-Cell Lymphoblastic Leukemia is approximately 30.0 per 100,000 population.
Deep-dive into B-Cell Lymphoblastic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis